Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-label, Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors

Next Previous
Trial Profile

A Phase 2, Open-label, Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vobramitamab duocarmazine (Primary)
  • Indications Adenocarcinoma; Anal cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms Tamarack
  • Sponsors MacroGenics

Most Recent Events

  • 18 Feb 2025 Status changed from active, no longer recruiting to completed.
  • 05 Nov 2024 According to a MacroGenics media release, companys expected funding requirements reflect anticipated expenditures related to the completion of the Phase 2 TAMARACK and LORIKEET clinical trials, as well as MacroGenics other ongoing clinical and preclinical studies.
  • 05 Nov 2024 According to a MacroGenics media release, company anticipates that its cash, cash equivalents and marketable securities balance of $200.4 million as of Sep 30, 2024, plus the $40.0 million upfront payment anticipated from TerSera related to the MARGENZA transaction, less an $8.0 million amendment fee to be paid to current commercialization partner, in addition to projected and anticipated future payments from partners should support its cash runway into 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top